SNMMI has applied for 1.5 hours of CE Credit for this in-person event. Please note that seating is limited and registration will be available on a first-come, first-served basis.
6:30-8:00 pm Educational Program
Several new radiopharmaceuticals are now being used in both large academic and small practice settings to stage and identify local and metastatic prostate cancer, including the recently approved Ga-68 PSMA-11 and 18F-DCFPyL. In addition, the FDA in March 2022 approved Lu 177 vipivotide tetraxetan to treat PSMA-positive metastatic castration-resistant prostate cancer. Given these new advancements in diagnosis and treatment, the panel will present a comprehensive, interactive session addressing the changing landscape of prostate cancer patient management.
6:30 Welcome and Introductions
Ila Sethi, MD, Clinical Site Director, Nuclear Medicine, Emory University Hospital
6:30 - 6:55 pm Nuclear Medicine Perspective
David M Schuster, MD, FACR, Professor of Radiology and Imaging Sciences and Urology, Emory University Hospital
6:55 - 7:20 pm Oncologist's Perspective
Mehmet Asim Bilen, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
7:20 - 7:45 pm Radiation Oncologist's Perspective
Ashesh B. Jani, MD, MSEE, FASTRO, James C. Kennedy Professor, Department of Radiation Oncology, Winship Cancer Institute of Emory University